
Outputs & Publications
We produce a range of outputs: reports for our stakeholders from each of our Programmes; journal articles reporting cutting edge methods and insights; dashboards of therapeutic interventions and diagnostic tests in development for COVID-19; and exciting novel digital tools such as ScanMedicine - a comprehensive database of clinical trials and FDA-approved medical devices, diagnostics and digital applications. Click below to view examples of our different types of outputs.
Horizon Scan for Advanced Therapy Medicinal Products

Advanced Therapy Medicinal Products (ATMPs) are novel therapies based on cells, genes or tissues with the potential to address the underlying cause of the diseases. ATMPs come with potentially significant implementation challenges, high costs and regulatory & assessment uncertainties.
DownloadCombination therapies for COVID-19: An overview of the clinical trials landscape

In this paper, we provide an overview of the current clinical trial landscape for combination therapeutics targeting COVID-19 through weekly scanning of national and international clinical trial registries. Our analysis delves specifically into dual combination therapies in what can be defined as “pivotal clinical trials” (active, randomised, controlled and at least phase II), with a focus on new and repurposed therapeutic candidates that have shown positive signals and/or been granted authorisation for emergency use based on positive efficacy and safety data.
Visit WebsiteIdentification of COVID-19 Diagnostics Using Horizon Scanning Approaches to Inform Decision Making

In response to the COVID-19 pandemic the Innovation Observatory has collated a comprehensive global dataset of SARS-CoV-2 diagnostic tests, supporting stakeholder in assessing priorities and mitigation options in response to testing challenges. Using manual and automated horizon scanning approaches, our diagnostic landscape has provided key insights into the evolution of technological innovations, their regulation and […]
DownloadRepurposing of therapeutics for SARS-CoV-2 an overview of current evidence

There is a need for effective and accessible treatments for SARS-CoV-2 and repurposing drugs already approved for other indications may provide a rapid alternative to de-novo drug development. This report provides a rapid evidence overview (evidence map and narrative synthesis) of the drug repurposing preclinical research landscape (in vivo, in vitro and in silico studies) […]
Download